REGENXBIO Inc

REGENXBIO Inc. is a leading biotechnology company headquartered in Rockville, Maryland. The company employs 382 individuals and boasts an annual revenue of $480 million. REGENXBIO is dedicated to revolutionizing the treatment of severe diseases with significant unmet medical needs through its groundbreaking gene therapy innovations. REGENXBIO specializes in the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy products. Their proprietary AAV gene delivery platform, known as the NAV® Technology Platform, grants them exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9, and AAVrh10. These vectors are utilized to deliver therapeutic genes directly into target cells, offering the potential for long-lasting treatment benefits. REGENXBIO's mission is to transform the lives of patients suffering from debilitating diseases by leveraging the power of its NAV Technology Platform. The company pursues this mission through both internal research and development efforts and by collaborating with third-party licensees who utilize the NAV Technology Platform to develop their own gene therapies. For more information or to explore potential collaborations, interested parties can visit REGENXBIO's website at regenxbio.com.